![]() |
市場調查報告書
商品編碼
1755978
2032 年彈性成像市場預測:按模式、技術、應用和地區分類的全球分析Elastography Imaging Market Forecasts to 2032 - Global Analysis By Modality (Ultrasound Elastography and Magnetic Resonance Elastography (MRE)), Technology (Strain Elastography, Shear Wave Elastography), Application and By Geography |
根據 Stratistics MRC 的數據,全球彈性成像市場預計在 2025 年達到 24.9 億美元,到 2032 年將達到 46.5 億美元,預測期內的複合年成長率為 9.32%。
一種名為彈性成像的非侵入性醫學成像技術,透過測量組織彈性或硬度來檢測異常。為了檢測改變組織硬度的疾病,例如肝纖維化或腫瘤,需要對組織施加機械力,並觀察其如何變形。彈性成像通常與核磁共振成像 (MRI) 或超音波結合使用,以提供定量的即時數據,從而更早發現疾病並提高診斷準確性。彈性成像在肌肉骨骼成像、肝病學和癌症領域特別有用,它提供了一種比侵入性切片檢查技術更準確、更安全的替代方案。
慢性肝病和癌症增加
彈性成像是一種精準、非侵入性的方法來識別肝臟腫瘤和纖維化,從而促進早期診斷和治療。全球肝硬化、脂肪肝和肝炎的發生率不斷上升,推動了對先進成像技術的需求。彈性成像能夠測量組織硬度,也能透過表徵腫瘤特徵使癌症患者受益。為了改善患者預後並減少切片檢查需求,醫療保健提供者擴大使用這項技術。因此,彈性成像在醫院和診斷機構的臨床應用中越來越被接受。
彈性成像系統高成本
彈性成像系統需要大量的初始投資,許多醫療機構難以承受。此外,維護和營運成本對於資源匱乏的醫療機構來說也是一筆額外的負擔。資金限制迫使小型醫院和診斷機構選擇傳統的影像技術。這一高昂的成本限制制約了先進彈性成像技術的市場滲透。因此,彈性成像市場的整體成長潛力受到抑制。
科技進步與人工智慧的融合
人工智慧 (AI) 與機器學習技術正在融合,以變革影像分析。透過自動化影像解讀和識別人眼可能遺漏的細微異常,人工智慧提高了診斷的準確性。這帶來了更具可重複性的觀察,並減少了對操作人員的依賴。人工智慧還可以指導治療並促進即時影像品質評估。隨著人工智慧、巨量資料和雲端運算的結合,提供日益全面和準確的診斷能力,全球市場預計將進一步擴大。
缺乏訓練有素的專業人員和標準化通訊協定
這項技術學習難度高,令許多醫療從業人員猶豫不決。訓練設施不足進一步加劇了不同地區醫療能力的差異。此外,缺乏標準化的影像技術導致治療結果參差不齊,診斷可靠性降低。這些不一致性阻礙了它在標準醫療實踐中的廣泛應用。因此,營運效率低和用戶質疑都限制了市場擴張。
COVID-19的影響
新冠疫情對彈性成像市場造成了重大衝擊。由於擇期手術延遲以及醫療保健重點轉向疫情防治,該市場最初出現下滑。供應鏈中斷和產能下降進一步阻礙了市場成長。然而,隨著醫療體系的調整,需求逐漸回升,尤其是在彈性成像技術被證明可用於評估長期新冠患者肺纖維化等器官損傷方面。對非侵入性診斷的日益關注以及推遲檢測的積壓,正在推動市場穩步復甦和成長。
超音波彈性成像市場預計將在預測期內成長至最大
預計超音波彈性成像領域將在預測期內佔據最大的市場佔有率,因為與MRI等其他成像方式相比,它具有非侵入性和成本效益的特性。彈性成像可以即時可視化並定量評估組織硬度,有助於早期發現和監測疾病。肝病和乳癌等慢性疾病的盛行率不斷上升,進一步推動了其作為首選診斷工具的應用。與傳統超音波相比,它能夠提供更多資訊,尤其是在識別惡性組織方面,從而減少了侵入性切片檢查的需求。此外,技術的不斷進步和醫療專業人員意識的不斷提高,正在不斷擴大其臨床應用和市場規模。
心臟病學領域預計在預測期內以最高複合年成長率成長
循環系統領域需要先進的診斷工具,預計在預測期內將達到最高成長率。彈性成像技術提供了一種非侵入性方法來評估心肌僵硬程度並識別纖維化變化,這對於早期發現疾病至關重要。它能夠量化組織彈性,為診斷心臟衰竭和心肌病等疾病提供寶貴的見解。此外,對超越傳統成像模式的全面心臟評估的需求日益成長,這推動了彈性成像技術的普及。因此,彈性成像已成為心血管診斷中日益重要的工具,為市場成長做出了重大貢獻。
在預測期內,亞太地區預計將佔據最大的市場佔有率,這得益於醫療基礎設施投資的增加以及人們對疾病早期診斷意識的不斷增強。肝病、癌症和慢性病盛行率的上升刺激了對先進成像技術的需求。中國、日本和印度等國家正在醫院和診斷環境中迅速採用彈性成像技術。技術進步加上老年人口的成長,支撐了長期成長前景。此外,有利的政府政策和日益成長的醫療旅遊也進一步推動了該地區市場的擴張。
在預測期內,由於創新診斷技術的早期應用,北美地區預計將呈現最高的複合年成長率。領先的醫療設備製造商和研究機構的強大影響力有助於持續的產品開發。乳癌、肝纖維化和心血管疾病的發生率不斷上升,推動了彈性成像的臨床應用。高昂的醫療支出、強大的保險覆蓋範圍以及完善的法律規範正在推動市場持續成長。美國在該區域市場佔據主導地位,受益於技術整合、熟練的專業人員以及對非侵入式成像解決方案日益成長的需求。
According to Stratistics MRC, the Global Elastography Imaging Market is accounted for $2.49 billion in 2025 and is expected to reach $4.65 billion by 2032 growing at a CAGR of 9.32% during the forecast period. A non-invasive medical imaging method called elastography imaging gauges the elasticity or stiffness of tissues to find anomalies. In order to detect disorders where tissue stiffness varies, such as liver fibrosis and tumours, it applies mechanical force to tissues and examines how they deform in response. Elastography, which is frequently utilised in conjunction with MRI or ultrasound, offers quantitative, real-time data that improves early disease identification and diagnostic precision. It is particularly useful in musculoskeletal imaging, hepatology, and cancer, providing a more accurate and safer substitute for invasive biopsy techniques.
Rising prevalence of chronic liver diseases and cancer
Elastography provides a precise and non-invasive way to identify liver tumours and fibrosis, facilitating early diagnosis and therapy. The need for sophisticated imaging technologies is fuelled by rising rates of cirrhosis, fatty liver disease, and hepatitis worldwide. Elastography's capacity to measure tissue stiffness also helps cancer patients by enhancing tumour characterisation. In an effort to improve patient outcomes and lessen the necessity for biopsies, healthcare providers are using this technology more and more. Elastography imaging is therefore becoming increasingly clinically accepted in hospitals and diagnostic facilities.
High cost of elastography imaging systems
A large initial investment is frequently needed for these systems, which many healthcare organisations cannot afford. Institutions with tight resources are further burdened by maintenance and operating expenses. Because of financial limitations, smaller hospitals and diagnostic facilities could choose traditional imaging techniques. The market penetration of sophisticated elastography technologies is constrained by this expensive hurdle. Consequently, the elastography imaging market's overall growth potential is impeded.
Technological advancements and integration with AI
Artificial Intelligence (AI) and machine learning technologies are being combined to transform picture analysis. By automating image interpretation and identifying minor anomalies that the human eye frequently misses, artificial intelligence improves diagnosis accuracy. As a result, findings are more reproducible and operator dependence is decreased. AI also directs treatments and makes it easier to evaluate image quality in real time. Global market increase is anticipated as AI, big data, and cloud computing combine to provide increasingly more thorough and accurate diagnostic capabilities.
Lack of skilled professionals and standardized protocols
The high learning curve associated with the technology makes many healthcare practitioners hesitant to invest in it. The disparity in competence between locations is further widened by inadequate training facilities. Furthermore, variable outcomes and decreased diagnostic confidence are caused by the lack of standardised imaging techniques. Wider incorporation into standard medical practice is discouraged by this discrepancy. Consequently, both operational inefficiency and user scepticism limit market expansion.
Covid-19 Impact
The COVID-19 pandemic significantly impacted the elastography imaging market. Initially, there was a downturn due to deferred elective procedures and a shift in healthcare priorities towards managing the pandemic. Supply chain disruptions and reduced manufacturing capabilities further hindered market growth. However, as healthcare systems adapted, there was a resurgence in demand, particularly as elastography proved valuable in assessing organ damage, including lung fibrosis in long-COVID patients. The increased focus on non-invasive diagnostic methods and the backlog of postponed examinations are now driving a steady recovery and growth in the market.
The ultrasound elastography segment is expected to be the largest during the forecast period
The ultrasound elastography segment is expected to account for the largest market share during the forecast period, due to its non-invasive nature and cost-effectiveness compared to other imaging modalities like MRI. It offers real-time visualization and quantitative assessment of tissue stiffness, aiding in early disease detection and monitoring. The growing prevalence of chronic conditions like liver diseases and breast cancer further drives its adoption as a preferred diagnostic tool. Its ability to provide additional information beyond conventional ultrasound, particularly in identifying malignant tissues, reduces the need for invasive biopsies. Moreover, ongoing technological advancements and increasing awareness among healthcare professionals are continuously expanding its clinical applications and market reach.
The cardiology segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cardiology segment is predicted to witness the highest growth rate, due to necessitating advanced diagnostic tools. Elastography offers a non-invasive method for assessing myocardial stiffness and identifying fibrotic changes, crucial for early disease detection. Its ability to quantify tissue elasticity provides valuable insights for diagnosing conditions like heart failure and cardiomyopathy. Furthermore, the rising demand for comprehensive cardiac assessments that go beyond traditional imaging methods fuels its adoption. This makes elastography an increasingly vital tool in cardiovascular diagnostics, significantly contributing to the market's growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by increasing investments in healthcare infrastructure and rising awareness about early disease diagnosis. Growing prevalence of liver diseases, cancer, and chronic conditions fuels demand for advanced imaging technologies. Countries like China, Japan, and India are rapidly adopting elastography in both hospital and diagnostic settings. Technological advancements, coupled with expanding geriatric populations, support long-term growth prospects. Moreover, favorable government policies and expanding medical tourism further accelerate market expansion in the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to early adoption of innovative diagnostic technologies. Strong presence of major healthcare equipment manufacturers and research institutions contributes to continuous product development. Rising incidence of breast cancer, liver fibrosis, and cardiovascular diseases encourages clinical use of elastography. High healthcare spending, robust insurance coverage, and established regulatory frameworks drive consistent market growth. The U.S. dominates the regional market, benefiting from technological integration, skilled professionals, and increasing demand for non-invasive imaging solutions.
Key players in the market
Some of the key players profiled in the Elastography Imaging Market include Canon Medical Systems Corporation, GE HealthCare, Koninklijke Philips N.V., FUJIFILM Corporation, Mindray Medical International Limited, Esaote S.p.A, Siemens Healthineers, Hitachi, Ltd., Samsung Medison Co., Ltd., SuperSonic Imagine, Resoundant, Inc., Hologic, Inc., Toshiba America Medical Systems, Inc., Clarius Mobile Health, Carestream Health, Advanced Instrumentations, BK Medical Holding Company, Inc. and SonoScape Medical Corp.
In January 2025, GE HealthCare strengthened its partnership with the ESR as a Platinum Supporter for ECR 2025. This expanded collaboration focuses on redefining medical imaging innovation. The partnership emphasizes precision care, innovation and sustainability in radiology, all of which are highly relevant to elastography imaging advancements.
In June 2024, Canon Medical Systems USA, Inc. entered into a strategic partnership with Hermes Medical Solutions through a Sales Agent Agreement. The partnership is designed to broaden access to innovative solutions, improve clinical outcomes, and complement Canon's Vitrea Oncology offerings with advanced theragnostic capabilities.
In July 2023, GE HealthCare extended its collaboration with Elekta to expand access to precision radiation therapy solutions in India. This partnership aims to provide comprehensive imaging and treatment offerings for cancer patients, integrating diagnostic and therapeutic solutions. The alliance is designed to enable more efficient, precise, and personalized care, which aligns with the application of elastography in oncology for tumour characterization and treatment planning